Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice

Hee Young Chae, byungwan lee, Seung Hoon Oh, You Ran Ahn, Jae Hoon Chung, Yong Ki Min, Myung Shik Lee, Moon Kyu Lee, Kwang Won Kim

Research output: Contribution to journalArticle

25 Citations (Scopus)

Abstract

Hypoxic damage is one of the major causes of islet graft failure and VEGF is known to play a crucial role in revascularization. To address the effectiveness of a cationic lipid reagent as a VEGF gene carrier, and the beneficial effect of VEGF-transfected islets on glycemic control, we used effectene lipid reagent in a transfection experiment using mouse islets. Transfection efficiencies were highest for 4 μg/μL cDNA and 25 μL effectene and cell viabilities were also satisfactory under this condition, and the overproduction of VEGF mRNA and protein were confirmed from conditioned cells. A minimal number of VEGF-transfected islets (100 IEQ/animal) were transplanted into streptozotocin (STZ)-induced diabetic mice. Hyperglycemia was not controlled in the islet transplantation (IT)-alone group (0/8) (non-diabetic glucose mice number/total recipient mice number) or in the IT-pJDK control vector group (0/8). However, hyperglycemia was completely abrogated in the IT-pJDK-VEGF transduced group (8/8), and viable islets and increased VEGF-transfected grafts vascularization were observed in renal capsules. These studies support the usefulness of VEGF-transfected islet delivery using a cationic lipid reagent to achieve euglycemia using a minimal number of islets.

Original languageEnglish
Pages (from-to)513-523
Number of pages11
JournalExperimental and Molecular Medicine
Volume37
Issue number6
DOIs
Publication statusPublished - 2005 Dec 31

Fingerprint

Streptozocin
Liposomes
Vascular Endothelial Growth Factor A
Islets of Langerhans Transplantation
Lipids
Grafts
Hyperglycemia
Transfection
Transplants
Capsules
Cell Survival
Animals
Complementary DNA
Genes
Cells
Kidney
Glucose
Control Groups
Messenger RNA

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry

Cite this

Chae, Hee Young ; lee, byungwan ; Oh, Seung Hoon ; Ahn, You Ran ; Chung, Jae Hoon ; Min, Yong Ki ; Lee, Myung Shik ; Lee, Moon Kyu ; Kim, Kwang Won. / Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice. In: Experimental and Molecular Medicine. 2005 ; Vol. 37, No. 6. pp. 513-523.
@article{07df0fe73261490c82f0cc66f61fa400,
title = "Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice",
abstract = "Hypoxic damage is one of the major causes of islet graft failure and VEGF is known to play a crucial role in revascularization. To address the effectiveness of a cationic lipid reagent as a VEGF gene carrier, and the beneficial effect of VEGF-transfected islets on glycemic control, we used effectene lipid reagent in a transfection experiment using mouse islets. Transfection efficiencies were highest for 4 μg/μL cDNA and 25 μL effectene and cell viabilities were also satisfactory under this condition, and the overproduction of VEGF mRNA and protein were confirmed from conditioned cells. A minimal number of VEGF-transfected islets (100 IEQ/animal) were transplanted into streptozotocin (STZ)-induced diabetic mice. Hyperglycemia was not controlled in the islet transplantation (IT)-alone group (0/8) (non-diabetic glucose mice number/total recipient mice number) or in the IT-pJDK control vector group (0/8). However, hyperglycemia was completely abrogated in the IT-pJDK-VEGF transduced group (8/8), and viable islets and increased VEGF-transfected grafts vascularization were observed in renal capsules. These studies support the usefulness of VEGF-transfected islet delivery using a cationic lipid reagent to achieve euglycemia using a minimal number of islets.",
author = "Chae, {Hee Young} and byungwan lee and Oh, {Seung Hoon} and Ahn, {You Ran} and Chung, {Jae Hoon} and Min, {Yong Ki} and Lee, {Myung Shik} and Lee, {Moon Kyu} and Kim, {Kwang Won}",
year = "2005",
month = "12",
day = "31",
doi = "10.1038/emm.2005.64",
language = "English",
volume = "37",
pages = "513--523",
journal = "Experimental and Molecular Medicine",
issn = "1226-3613",
publisher = "Korean Society of Med. Biochemistry and Mol. Biology",
number = "6",

}

Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice. / Chae, Hee Young; lee, byungwan; Oh, Seung Hoon; Ahn, You Ran; Chung, Jae Hoon; Min, Yong Ki; Lee, Myung Shik; Lee, Moon Kyu; Kim, Kwang Won.

In: Experimental and Molecular Medicine, Vol. 37, No. 6, 31.12.2005, p. 513-523.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effective glycemic control achieved by transplanting non-viral cationic liposome-mediated VEGF-transfected islets in streptozotocin-induced diabetic mice

AU - Chae, Hee Young

AU - lee, byungwan

AU - Oh, Seung Hoon

AU - Ahn, You Ran

AU - Chung, Jae Hoon

AU - Min, Yong Ki

AU - Lee, Myung Shik

AU - Lee, Moon Kyu

AU - Kim, Kwang Won

PY - 2005/12/31

Y1 - 2005/12/31

N2 - Hypoxic damage is one of the major causes of islet graft failure and VEGF is known to play a crucial role in revascularization. To address the effectiveness of a cationic lipid reagent as a VEGF gene carrier, and the beneficial effect of VEGF-transfected islets on glycemic control, we used effectene lipid reagent in a transfection experiment using mouse islets. Transfection efficiencies were highest for 4 μg/μL cDNA and 25 μL effectene and cell viabilities were also satisfactory under this condition, and the overproduction of VEGF mRNA and protein were confirmed from conditioned cells. A minimal number of VEGF-transfected islets (100 IEQ/animal) were transplanted into streptozotocin (STZ)-induced diabetic mice. Hyperglycemia was not controlled in the islet transplantation (IT)-alone group (0/8) (non-diabetic glucose mice number/total recipient mice number) or in the IT-pJDK control vector group (0/8). However, hyperglycemia was completely abrogated in the IT-pJDK-VEGF transduced group (8/8), and viable islets and increased VEGF-transfected grafts vascularization were observed in renal capsules. These studies support the usefulness of VEGF-transfected islet delivery using a cationic lipid reagent to achieve euglycemia using a minimal number of islets.

AB - Hypoxic damage is one of the major causes of islet graft failure and VEGF is known to play a crucial role in revascularization. To address the effectiveness of a cationic lipid reagent as a VEGF gene carrier, and the beneficial effect of VEGF-transfected islets on glycemic control, we used effectene lipid reagent in a transfection experiment using mouse islets. Transfection efficiencies were highest for 4 μg/μL cDNA and 25 μL effectene and cell viabilities were also satisfactory under this condition, and the overproduction of VEGF mRNA and protein were confirmed from conditioned cells. A minimal number of VEGF-transfected islets (100 IEQ/animal) were transplanted into streptozotocin (STZ)-induced diabetic mice. Hyperglycemia was not controlled in the islet transplantation (IT)-alone group (0/8) (non-diabetic glucose mice number/total recipient mice number) or in the IT-pJDK control vector group (0/8). However, hyperglycemia was completely abrogated in the IT-pJDK-VEGF transduced group (8/8), and viable islets and increased VEGF-transfected grafts vascularization were observed in renal capsules. These studies support the usefulness of VEGF-transfected islet delivery using a cationic lipid reagent to achieve euglycemia using a minimal number of islets.

UR - http://www.scopus.com/inward/record.url?scp=31344434146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=31344434146&partnerID=8YFLogxK

U2 - 10.1038/emm.2005.64

DO - 10.1038/emm.2005.64

M3 - Article

C2 - 16391512

AN - SCOPUS:31344434146

VL - 37

SP - 513

EP - 523

JO - Experimental and Molecular Medicine

JF - Experimental and Molecular Medicine

SN - 1226-3613

IS - 6

ER -